162162

ABSTRACT

[Object]

An object is to provide an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer.

[Means to Solve the Problem]

An anti-cancer pharmaceutical composition comprising a compound represented by the following general formula (I):



(I)

[wherein,

R represents a phenyl group substituted with 1 to 5 substituents selected from a halogen atom; a hydroxy group; a C_1-C_6 alkyl group; a halogeno C_1-C_6 alkyl group; a C_1-C_6 alkoxy group; a C_1-C_6 alkylthio group; an amino group which may be substituted with a substituent; a C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, C_7-C_{16} aralkyl, C_6-C_{10} aryloxy, C_7-C_{16} aralkyloxy and C_6-C_{10} arylthio group which may be substituted with a substituent; a C_1-C_7 aliphatic acyloxy group; a 4- to 7-membered saturated heterocyclic group containing nitrogen atom(s); a 5- or 6-membered aromatic heterocyclic group containing nitrogen atom(s); a nitro group; and a cyano group; and

X represents an oxygen atom or a sulfur atom] or a pharmacologically acceptable salt thereof, as an active ingredient,

and

an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer which is for administering simultaneously or separately at different times, containing an epidermal growth factor receptor

G00002

(EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor or a Raf kinase inhibitor; and a compound represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

[Selected Drawings]

None.